We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+36.31%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$890M
AUM Growth
+$233M
Cap. Flow
+$63.4M
Cap. Flow %
7.12%
Top 10 Hldgs %
74.13%
Holding
34
New
2
Increased
15
Reduced
2
Closed
8

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$40.6M
2
PCVX icon
Vaxcyte
PCVX
+$38.6M
3
VERA icon
Vera Therapeutics
VERA
+$23.7M
4
MRUS
Merus
MRUS
+$23M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$15.9M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$47.4M
2
AMAM
Ambrx Biopharma Inc
AMAM
+$20.5M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$10.1M
5
RNAM
Avidity Biosciences
RNAM
+$9.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$105M 11.84%
4,000,000
+1,050,000
+36% +$23M
VERA icon
2
Vera Therapeutics
VERA
$2.54B
$87.5M 9.83%
5,450,000
+2,625,971
+93% +$23.7M
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$78.2M 8.79%
1,675,000
+885,000
+112% +$40.6M
XENE icon
4
Xenon Pharmaceuticals
XENE
$6.32B
$71M 7.98%
1,845,000
– –
COGT icon
5
Cogent Biosciences
COGT
$6.79B
$65.9M 7.41%
5,566,026
+793,605
+17% +$9.1M
VRDN icon
6
Viridian Therapeutics
VRDN
$2.13B
$52.3M 5.88%
2,200,000
+10,341
+0.5% +$265K
AMAM
7
DELISTED
Ambrx Biopharma Inc
AMAM
$52.3M 5.87%
3,175,000
-1,628,447
-34% -$20.5M
PCVX icon
8
Vaxcyte
PCVX
$7.89B
$50.7M 5.7%
1,015,000
+815,000
+408% +$38.6M
NUVL
9
DELISTED
Nuvalent
NUVL
$48.5M 5.45%
1,150,000
+75,000
+7% +$2.84M
ELVN icon
10
Enliven Therapeutics
ELVN
$3.78B
$47.9M 5.39%
2,348,272
+616,907
+36% +$12.5M
CABA icon
11
Cabaletta Bio
CABA
$439M
$30.6M 3.44%
2,368,186
+533,186
+29% +$5.79M
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
$22.2M 2.49%
2,025,000
– –
ARWR icon
13
Arrowhead Research
ARWR
$12.1B
$21.8M 2.44%
610,000
+35,000
+6% +$1.21M
CLDX icon
14
Celldex Therapeutics
CLDX
$2.77B
$21.4M 2.41%
631,665
+135,842
+27% +$4.58M
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.84B
$20.9M 2.35%
997,596
+143,712
+17% +$2.99M
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.41B
$18.2M 2.05%
+775,000
New +$15.9M
IMVT icon
17
Immunovant
IMVT
$8.09B
$17.1M 1.92%
900,000
-540,999
-38% -$10.1M
ADVM
18
DELISTED
Adverum Biotechnologies
ADVM
$15.9M 1.79%
1,000,000
+500,000
+100% +$5.26M
CELC icon
19
Celcuity
CELC
$4.03B
$15.9M 1.78%
1,444,141
+53,369
+4% +$554K
KURA icon
20
Kura Oncology
KURA
$922M
$14.8M 1.66%
1,400,000
+195,042
+16% +$2.31M
ALPN
21
DELISTED
Alpine Immune Sciences Inc
ALPN
$13.6M 1.53%
1,325,000
– –
DAWN
22
DELISTED
Day One Biopharmaceuticals
DAWN
$8.83M 0.99%
739,661
– –
THRD
23
DELISTED
Third Harmonic Bio
THRD
$4.78M 0.54%
993,294
– –
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$2.81M 0.32%
312,553
– –
SYRE icon
25
Spyre Therapeutics
SYRE
$8.87B
$1.31M 0.15%
+116,324
New +$552K
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Commodore Capital held 34 positions worth $890M, up 35% from $657M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Commodore Capital deployed $63.4M of net new capital in Q2 2023, opening 2 new positions and adding to 15 existing holdings. Its largest new stake was IDEAYA Biosciences: 775,000 shares worth $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Ambrx Biopharma Inc, an estimated $20.5M trimmed.

  • Commodore Capital's largest Q2 2023 buy was IDEAYA Biosciences: 775,000 shares worth $18.2M.
  • Commodore Capital added most to Akero Therapeutics in Q2 2023, an estimated $40.6M increase.
  • Commodore Capital's biggest Q2 2023 reduction was Ambrx Biopharma Inc, cutting an estimated $20.5M.
  • Commodore Capital fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $47.4M.
  • Commodore Capital's ten largest holdings make up 74% of its $890M portfolio in Q2 2023.
  • Commodore Capital opened 2 new positions and closed 8 in Q2 2023.
  • Commodore Capital's portfolio value rose 35% quarter-over-quarter to $890M.

Based on Commodore Capital's 13F filing for Q2 2023, filed 14 Aug 2023.